These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1129 related items for PubMed ID: 21700252

  • 1. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.
    Mehran R, Pocock S, Nikolsky E, Dangas GD, Clayton T, Claessen BE, Caixeta A, Feit F, Manoukian SV, White H, Bertrand M, Ohman EM, Parise H, Lansky AJ, Lincoff AM, Stone GW.
    JACC Cardiovasc Interv; 2011 Jun; 4(6):654-64. PubMed ID: 21700252
    [Abstract] [Full Text] [Related]

  • 2. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.
    Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW.
    JACC Cardiovasc Interv; 2011 Feb; 4(2):191-7. PubMed ID: 21349458
    [Abstract] [Full Text] [Related]

  • 3. Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials).
    Ng VG, Baumbach A, Grinfeld L, Lincoff AM, Mehran R, Stone GW, Lansky AJ.
    Am J Cardiol; 2016 Jan 15; 117(2):186-91. PubMed ID: 26704028
    [Abstract] [Full Text] [Related]

  • 4. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
    Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R.
    JACC Cardiovasc Interv; 2011 Sep 15; 4(9):1011-9. PubMed ID: 21939942
    [Abstract] [Full Text] [Related]

  • 5. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
    Stone GW, Mehran R, Goldstein P, Witzenbichler B, Van't Hof A, Guagliumi G, Hamm CW, Généreux P, Clemmensen P, Pocock SJ, Gersh BJ, Bernstein D, Deliargyris EN, Steg PG.
    J Am Coll Cardiol; 2015 Jan 06; 65(1):27-38. PubMed ID: 25572507
    [Abstract] [Full Text] [Related]

  • 6. A risk score to predict bleeding in patients with acute coronary syndromes.
    Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW.
    J Am Coll Cardiol; 2010 Jun 08; 55(23):2556-66. PubMed ID: 20513595
    [Abstract] [Full Text] [Related]

  • 7. Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials.
    Giustino G, Mehran R, Bansilal S, Feit F, Lincoff M, Deliargyris EN, Kirtane AJ, Généreux P, Redfors B, Prats J, Bernstein D, Brener SJ, Skerjanec S, Lansky AJ, Francese DP, Dangas GD, Stone GW.
    Am J Cardiol; 2016 Jul 01; 118(1):6-16. PubMed ID: 27181566
    [Abstract] [Full Text] [Related]

  • 8. Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
    Parodi G, Antoniucci D, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga JZ, Stuckey T, Dudek D, Kornowski R, Hartmann F, Lansky AJ, Mehran R, Stone GW.
    JACC Cardiovasc Interv; 2010 Aug 01; 3(8):796-802. PubMed ID: 20723849
    [Abstract] [Full Text] [Related]

  • 9. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
    Rajagopal V, Lincoff AM, Cohen DJ, Gurm HS, Hu T, Desmet WJ, Kleiman NS, Bittl JA, Feit F, Topol EJ.
    Am Heart J; 2006 Jul 01; 152(1):149-54. PubMed ID: 16824845
    [Abstract] [Full Text] [Related]

  • 10. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R, Sardar P, Amin H, Swaminathan RV, Kim LK, Chatterjee S, Feldman DN.
    Am J Cardiol; 2014 Jul 15; 114(2):250-9. PubMed ID: 24890986
    [Abstract] [Full Text] [Related]

  • 11. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
    Exaire JE, Butman SM, Ebrahimi R, Kleiman NS, Harrington RA, Schweiger MJ, Bittl JA, Wolski K, Topol EJ, Lincoff AM, REPLACE-2 Investigators.
    Am Heart J; 2006 Jul 15; 152(1):157-63. PubMed ID: 16824849
    [Abstract] [Full Text] [Related]

  • 12. Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
    Chacko M, Lincoff AM, Wolski KE, Cohen DJ, Bittl JA, Lansky AJ, Tsuchiya Y, Betriu A, Yen MH, Chew DP, Cho L, Topol EJ.
    Am Heart J; 2006 May 15; 151(5):1032.e1-7. PubMed ID: 16644331
    [Abstract] [Full Text] [Related]

  • 13. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
    Feldman DN, Wong SC, Gade CL, Gidseg DS, Bergman G, Minutello RM.
    Am Heart J; 2007 Oct 15; 154(4):695-701. PubMed ID: 17892994
    [Abstract] [Full Text] [Related]

  • 14. Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
    Geisler T, Müller K, Karathanos A, Bocksch W, Gawaz M, Deliargyris E, Bernstein D, Lincoff AM, Mehran R, Dangas G, Stone GW.
    EuroIntervention; 2014 May 15; 10(1):97-104. PubMed ID: 24048204
    [Abstract] [Full Text] [Related]

  • 15. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G, Neumann FJ, Deliargyris EN, Mehran R, Mehilli J, Ferenc M, Schulz S, Schömig A, Kastrati A, Stone GW.
    Circ Cardiovasc Interv; 2012 Oct 15; 5(5):705-12. PubMed ID: 23048052
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
    Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, Lui HH, Bulle T, Lakkis N, Kovach R, Cohen DJ, Fish P, McCabe CH, Braunwald E, TIMI Study Group.
    J Am Coll Cardiol; 2006 Jun 20; 47(12):2364-73. PubMed ID: 16781360
    [Abstract] [Full Text] [Related]

  • 17. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    Lincoff AM, Steinhubl SR, Manoukian SV, Chew D, Pollack CV, Feit F, Ware JH, Bertrand ME, Ohman EM, Desmet W, Cox DA, Mehran R, Stone GW, Acute Catheterization and Urgent Intervention Triage strategY of Trial Investigators.
    JACC Cardiovasc Interv; 2008 Dec 20; 1(6):639-48. PubMed ID: 19463378
    [Abstract] [Full Text] [Related]

  • 18. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
    Olchanski N, Slawsky KA, Plent S, Kado C, Cyr PL.
    Hosp Pract (1995); 2010 Nov 20; 38(4):138-46. PubMed ID: 21068538
    [Abstract] [Full Text] [Related]

  • 19. Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
    Witzenbichler B, Mehran R, Guagliumi G, Dudek D, Huber K, Kornowski R, Stuckey TD, Fahy M, Parise H, Stone GW.
    JACC Cardiovasc Interv; 2011 Jul 20; 4(7):760-8. PubMed ID: 21777884
    [Abstract] [Full Text] [Related]

  • 20. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
    Bangalore S, Toklu B, Kotwal A, Volodarskiy A, Sharma S, Kirtane AJ, Feit F.
    BMJ; 2014 Nov 11; 349():g6419. PubMed ID: 25389143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.